Company / Gross Margin
GT Biopharma, Inc. Gross Margin History
FY2011-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
100.0%
FY2016
5-year range
6.6% / 100.0%
FY2012-FY2016
Trend
+1424.4%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin changed +1424% YoY in FY2016, a notable deviation from the 5-year average annual change of +313%.
Based on SEC 10-K filings.
100.0% in FY2016 with a 5-year CAGR of +590.9%.
Improved from 38.6% to 100.0% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +27.5pp
- 5-Year Change
- +590.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2016, gross margin increased 1424.4% year-over-year.
- Lowest gross margin in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | - | - |
| FY2017 | - | - |
| FY2016 | 100.0% | +1424.4% |
| FY2015 | 6.6% | -83.0% |
| FY2014 | 38.6% | -46.8% |
| FY2013 | 72.5% | +185.7% |
| FY2012 | -84.6% | +82.8% |
| FY2011 | -490.9% | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026